Protodioscin Restores Ovarian Function and Suppresses p53–Bax/Bcl-2–Mediated Apoptosis in a Doxorubicin-Induced Model of Ovarian toxicity
Advanced Pharmaceutical Bulletin · 11.07.2026
DOI: 10.34172/apb.46593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 11.07.2026. Verfasst von Amoura M Abou-El-Naga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
This study evaluated the protective effects of protodioscin against doxorubicin (DOX)-induced ovarian injury by examining its potential to modulate hormonal alterations and apoptosis-related pathways in a rat model.
Methods
Forty female Wistar rats were randomized into four groups: control, protodioscin (10 mg/kg orally for 14 days), DOX (10 mg/kg intraperitoneally on Day 7), and DOX plus protodioscin. Serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and 17β-estradiol (E2) were quantified using enzyme-linked immunosorbent assay. Ovarian histopathology and immunohistochemistry were performed to evaluate tissue integrity and expression of p53, CDK4, and Survivin. Gene expression of Bax and Bcl-2 was assessed using semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).
Results
DOX administration significantly reduced ovarian weight by 38.5% and uterine weight by 22.6% (P < 0.01) compared with controls, accompanied by marked hormonal alterations, including increased FSH and decreased LH, AMH, and E2 levels. DOX also increased p53 and Bax expression and decreased Bcl-2 expression, resulting in an elevated Bax/Bcl-2 ratio. Co-treatment with protodioscin significantly attenuated these changes, partially restoring hormonal levels and modulating apoptosis-related markers. Protodioscin reduced p53 and Bax expression while increasing Bcl-2, CDK4, and Survivin levels, leading to a marked reduction in the Bax/Bcl-2 ratio (P < 0.05).
Conclusion
Protodioscin exerts a protective effect against DOX-induced ovarian injury, likely through modulation of hormonal disturbances and apoptosis-related pathways. However, these findings should be interpreted with caution due to the absence of estrous cycle synchronization and the use of an acute DOX model.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Zoology, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt.
- Faculty of Oral and Dental Medicine, Delta University for Science and Technology, Gamasa, 35516, Egypt.
- Faculty of Medicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022, Nizhny Novgorod, Russia.
ORCID-Profile: Amoura M Abou-El-Naga, Maher Monir Akl
Zitieren
APA
Abou-El-Naga, A. M., Abd-Elhady, A. M., Abdraboh, M. E., Tag, Y. M., & Akl, M. M. (2026). Protodioscin Restores Ovarian Function and Suppresses p53–Bax/Bcl-2–Mediated Apoptosis in a Doxorubicin-Induced Model of Ovarian toxicity. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.46593
Vancouver
Abou-El-Naga AM, Abd-Elhady AM, Abdraboh ME, Tag YM, Akl MM. Protodioscin Restores Ovarian Function and Suppresses p53–Bax/Bcl-2–Mediated Apoptosis in a Doxorubicin-Induced Model of Ovarian toxicity. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.46593
BibTeX
@article{AbouElNaga2026,
author = {Abou-El-Naga, Amoura M and Abd-Elhady, Aya M and Abdraboh, Mohamed E and Tag, Yasmin M and Akl, Maher Monir},
title = {Protodioscin Restores Ovarian Function and Suppresses p53–Bax/Bcl-2–Mediated Apoptosis in a Doxorubicin-Induced Model of Ovarian toxicity},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
doi = {10.34172/apb.46593}
}
EUVIMED